Table 4.
Characteristic | HER2 Status |
P | |||
---|---|---|---|---|---|
Concordant(n = 133) |
Discordant(n = 35) |
||||
No. | % | No. | % | ||
Age at primary diagnosis, years | |||||
Mean | 47.04 | 52.26 | .013 | ||
SD | 11.27 | 9.42 | |||
Menopausal status | |||||
Premenopausal | 76 | 57 | 12 | 34 | .023 |
Postmenopausal | 57 | 43 | 22 | 63 | |
Unknown | 0 | 0 | 1 | 3 | |
ER status | |||||
Positive | 68 | 51 | 18 | 51 | .993 |
Negative | 64 | 48 | 17 | 49 | |
Unknown | 1 | 1 | 0 | 0 | |
PR status | |||||
Positive | 45 | 34 | 15 | 43 | .368 |
Negative | 85 | 64 | 20 | 57 | |
Unknown | 3 | 2 | 0 | 0 | |
Trastuzumab | |||||
None | 77 | 58 | 24 | 69 | .251 |
Before biopsy | 56 | 42 | 11 | 31 | |
Tumor grade | |||||
I | 0 | 0 | 2 | 6 | < .001 |
II | 20 | 15 | 10 | 28 | |
III | 107 | 80 | 22 | 63 | |
Unknown | 6 | 5 | 1 | 3 | |
Distant metastatic site | |||||
Without visceral | 46 | 35 | 16 | 45 | .225 |
With visceral | 87 | 65 | 19 | 55 |
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; SD, standard deviation.